Israeli medtech startup Vensica Therapeutics, which has developed a type of needle free tech too inject meds into a person’s bladder, raised $16 Million in a fundraising round led by Israel Biotech Fund (“IBF”), a venture fund investing in Israeli and Israeli-related biotechnology and pharmaceutical companies
Founded in 2015 by Avner Geva, (Yale, B.Sc, Technion, M.Sc), Vensica is a urology therapeutics company developing a unique platform for drug delivery for several urinary bladder indications, based on a proprietary ultrasound-assisted drug delivery system.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Needle free injections sounds like something out of Star Trek. But think of all of the benefits?
Medical personnel will no longer need to risk getting [oked with a dirty needle. No more need for finding a vein in an emergency situation. And people with chronic conditions will no longer need to continually inject themselves, causing scaring, pain and other problems.
And such a device can be used for multiple patients. Vaccinate countless people in one day with the same device connected to a tube filled with whatever the medication may be. No need to prepare a new needle for each patient.
But for now, this tech is limited to a specific type of medication on a specific part of the body. But it’s a start.
Vensica’s needle-free platform for drug delivery will be utilized for botulinum toxin type A delivery into the urinary bladder for the treatment of different urological indications including overactive bladder, neurogenic bladder, and interstitial cystitis. Today’s gold standard treatment requires needle injections of the neurotoxin into the bladder wall. Vensica’s needle-free platform is expected to enable a far superior patient experience, to resolve many needle-associated issues, including pain, urinary retention, and to make a generally more complicated procedure easier.
Vensica’s platform is also anticipated to facilitate a more efficacious treatment through a more uniform delivery of the neurotoxin to the bladder wall.
Vensica CEO Avner Geva, said, “Closing this investment round is an exceptional step for Vensica. Together with our partner and shareholder, Merz Therapeutics, and with the necessary funding, we are poised to plan and complete clinical and regulatory processes that will enable us to bring innovative and less invasive treatment of bladder diseases to the market.”
Vensica Chair, Nissim Darvish, M.D., Ph.D., added, “It is our pleasure to welcome and thank our new investors, IBF and Agriline, joining our longstanding supporters Laborie, Lew Pell and The Trendlines Group. Vensica’s team will work hard to get this solution to patients worldwide suffering from overactive bladder as well as other urinary bladder indications.”